[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"University of Liverpool\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":322},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,12,0,[8,48,70,95,123,150,172,195,228,252,274,295],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":26,"conditions":27,"keywords":29,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":36,"lastUpdatePostDateStruct":37,"startDateStruct":40,"completionDateStruct":42,"leadSponsor":44,"locationsCount":47},"100419780","phase-1-agile-early-phase-platform-trial-for-covid-19-100419780",false,"NCT04746183","AGILE (Early Phase Platform Trial for COVID-19)","AGILE: Seamless Phase I\u002FIIa Platform for the Rapid Evaluation of Candidates for COVID-19 Treatment","AGILE","Master Protocol Inclusion Criteria:\n\n1. Adults (≥18 years) with laboratory-confirmed\\* SARS-CoV-2 infection (PCR)\n2. Ability to provide informed consent signed by study patient or legally acceptable representative\n3. Women of childbearing potential (WOCBP) and male patients who are sexually active with WOCBP must agree to use a highly effective method of contraception (as outlined in the protocol) from the first administration of trial treatment, throughout trial treatment and for the duration outlined in the candidate-specific trial protocol after the last dose of trial treatment\n\n   * If any CSTs are included in the community setting, the CST protocol will clarify whether patients with suspected SARS-CoV-2 infection are also eligible.\n\nStandard additional criteria that may be applied per CST protocol:\n\nGroup A (severe disease) 4a. Patients with clinical status of Grades 4 (hospitalised, oxygen by mask or nasal prongs), 5 (hospitalised, on non-invasive ventilation, or high flow oxygen), 6 (hospitalised, intubation and mechanical ventilation) or 7 (ventilation and additional organ support - pressors, renal replacement therapy (RRT), extracorporeal membrane oxygenation (ECMO)), as defined by the WHO clinical severity score, 9-point ordinal scale.\n\nGroup B (mild-moderate disease) 4b. Ambulant or hospitalised patients with the following characteristics peripheral capillary oxygen saturation (SpO2) \\>94% RA N.B. The CST protocol inclusion criteria will take precedence over the master protocol inclusion criteria.\n\nCST-2 Inclusion Criteria:\n\nFor the purpose of the EIDD-2801 candidate-specific trial the following inclusion criteria have been amended from the Master protocol to:\n\n1\\. Male or female ≥ 60 years old or ≥50 years old with at least one well controlled comorbidity: cardiovascular disease, chronic lung disease (e.g. COPD, or pulmonary hypertension), immune deficiency (taking the equivalent of 20 mg prednisone daily, chemotherapy, or immune modulating biologic therapies), diabetes (treated with insulin or oral medications), BMI≥30, or hypertension requiring medication with laboratory confirmed SARS-CoV-2 infection (PCR) .\n\n3\\. Women of childbearing potential (WOCBP) and male patients who are sexually active with WOCBP must agree to use two effective methods of contraception, one of which should be highly effective (as outlined in the protocol). For women, from the first administration of trial treatment, throughout trial and up to 50 days after the last follow up visit (50 days after day 29) and for men with female partners of child bearing potential, from the first administration until 100 days after last follow up visit (100 days after day 29).\n\n4\\. Group B (mild-moderate disease): Ambulant with the following characteristics peripheral capillary oxygen saturation (SpO2) \\>94% RA (NB this differs to the Master Protocol which also includes hospitalised patients in this group).\n\nAdditional criteria specific to this candidate are:\n\n5\\. Has signs or symptoms of COVID-19 that began within 5 days of the planned first dose of study drug.\n\n6\\. Is in generally good health (except for current respiratory infection) and is free of uncontrolled chronic conditions.\n\n7\\. Is willing and able to comply with all study procedures and attending clinic visits through the 4th week.\n\n8\\. Has someone, aged ≥ 16 living in the same household during the dosing period.\n\nCST-6 Additional inclusion criteria:\n\n1. Group A (severe disease). Patients with clinical status of Grades 5 (hospitalised, oxygen by mask or nasal prongs), 6 (hospitalised, on non-invasive ventilation, or high flow oxygen as defined by the WHO Clinical Progression Scale (WHO, 2020)).\n2. Less than or equal to 14 days from onset of COVID-19 symptoms\n\nCST-8 Inclusion Criteria:\n\n1. For the purpose of CST-8, criteria 1 has been amended from the Master Protocol to:\n\n   Adults (≥18 years) outpatients positive lateral flow test at screening or baseline Day 1, who are within 5 days of symptom onset prior to the planned first dose of study drug.\n2. Criteria 3 has been amended from the Master Protocol to:\n\nWomen of childbearing potential (WOCBP) and male participants who are sexually active with WOCBP must agree to use a highly effective method of contraception (as outlined in section 5.5 of the Master Protocol) for the duration of the treatment and for six weeks following the last dose.\n\nAdditional criteria specific to CST-8 are:\n\n* Initial onset of COVID-19 signs\u002Fsymptoms within 5 days prior to the day of randomisation and at least 1 of the current specified COVID-19 signs\u002Fsymptoms (listed on the NHS website) present on the day of randomisation\n* Is willing and able to comply with all study procedures and attending clinic visits\n\nCST-9a Inclusion Criteria:\n\nFor the purpose of CST-9a, criteria 1 has been amended from the Master Protocol to:\n\n1. Adults (\\>\u002F= 18 years of age) with a positive SARS-CoV-2 lateral flow test on screening or Day 1, who are at high risk (as defined in UK DHSC criteria) of progressing to severe COVID-19 disease, within 3 days of symptom onset, with at least one symptom of COVID-19 infection present on the day of randomization and are with mild- moderate disease severity at enrolment.\n\n   Criterion 2 has been amended from the Master Protocol to:\n2. Ability to provide informed consent signed by trial participant or legally acceptable representative and are willing and able to comply with all trial procedures and attending clinic visits\n\n   Criterion 3 has been amended from the Master Protocol to:\n3. Women of childbearing potential (WOCBP) and male participants who are sexually active with WOCBP must agree to use two effective methods of contraception, one of which must be highly effective for the duration of the treatment and for 90 Days following the last dose\n\nMaster Protocol Exclusion Criteria:\n\n1. Alanine aminotransferase (ALT) and\u002For aspartate aminotransferase (AST) \\>5 times the upper limit of normal (ULN)\n2. Stage 4 severe chronic kidney disease or requiring dialysis (i.e., estimated glomerular filtration rate \\\u003C30 mL\u002Fmin\u002F1.73 m\\^2)\n3. Pregnant or breast feeding\n4. Anticipated transfer to another hospital which is not a study site within 72 hours\n5. Allergy to any study medication\n6. Patients taking other prohibited drugs (as outline in CST protocol) within 30 days or 5 times the half-life (whichever is longer) of enrolment\n7. Patients participating in another CTIMP trial\n\nN.B. The CST protocol exclusion criteria will take precedence over the master protocol exclusion criteria.\n\nCST-9a Exclusion Criteria:\n\nExclusion criteria has been amended from master protocol as:\n\n1. Prior SARS-CoV-2 infection \\\u003C90 days before enrolment and\u002For received any COVID-19 vaccine dose \\\u003C90 days before enrolment\n2. Alanine aminotransferase (ALT) \\>3 times the upper limit of normal (ULN) or Active Liver disease\n3. History or current evidence of cirrhosis\n4. Receiving dialysis or have known moderate to severe renal impairment (defined as CKD stage 4 or 5) or current acute kidney injury on most recent eGFR in the past 6 months\n5. Pregnant or breast feeding\n6. Anticipated transfer to another hospital which is not a trial site within 72 hours\n7. Known allergy to any trial medication\n8. Swallowing difficulties\n9. Currently receiving ALG-097558, Paxlovid, molnupiravir or remdesivir or any SoC therapy for COVID-19 at the time of screening\n10. Received sotrovimab at any point during the current SARS-CoV-2 infection\n11. Oxygen saturations \\\u003C94% on room air\n12. Urgent or expected need for nasal high-flow oxygen therapy or positive pressure ventilation, invasive mechanical ventilation or ECMO.\n13. Participants who have taken or require treatment with a comedication that is a strong CYP450 3A4 inhibitor (atazanavir, clarithromycin, itraconazole, posaconazole, voriconazole, nefazodone, nelfinavir, grapefruit juice, HIV protease inhibitors), strong CYP450 3A4 inducers (rifampin, phenytoin, carbamazepine, St. John's Wort) or sensitive substrates of CYP450 2C8 and 2B6 (repaglinide, rosiglitazone, paclitaxel, bupropion) within at least 2 weeks or 5 half-lives (whichever is longer) before the planned first dose of study drug.\n14. Participating in another CTIMP trial\n\nCST-9b Exclusion criteria:\n\n1. Prior SARS-CoV-2 infection diagnosed \\\u003C90 days before enrolment and\u002For received any COVID-19 vaccine dose \\\u003C90 days before enrolment\n2. Alanine aminotransferase (ALT) \\>3 times the upper limit of normal (ULN) or Active Liver disease\n3. History or current evidence of cirrhosis\n4. Receiving dialysis or have known severe renal impairment defined as CKD stage 5 (an eGFR \\\u003C15 mL\u002Fmin\u002F1.73 m2 at screening, or current acute kidney injury in most recent eGFR in past 6 months.\n5. Pregnant or breast feeding\n6. Anticipated transfer to another hospital which is not a trial site within 72 hours\n7. Known allergy to any trial medication\n8. Swallowing difficulties\n9. Currently receiving ALG-097558, Paxlovid, molnupiravir or remdesivir or any standard of care antiviral therapy for COVID-19 at the time of screening\n10. Received sotrovimab at any point during the current SARS-CoV-2 infection prior to enrolment\n11. Oxygen saturations \\\u003C94% on room air. NOTE: Participants on stable oxygen therapy, including use of NIPPV (non-invasive positive pressure ventilation), for a pre-existing medical condition (e.g., COPD) may be included with oxygen saturation of \\\u003C94% on room air, provided there is no new increased oxygen requirement.\n12. Urgent or expected need for nasal high-flow oxygen therapy or positive pressure ventilation, invasive mechanical ventilation or ECMO.\n13. Participants who have taken or require treatment with a comedication that is a strong CYP450 3A4 inhibitor (atazanavir, clarithromycin, itraconazole, posaconazole, voriconazole, nefazodone, nelfinavir, grapefruit juice, HIV protease inhibitors), strong CYP450 3A4 inducers (rifampin, phenytoin, carbamazepine, St. John's Wort) or sensitive substrates of CYP450 2C8 and 2B6 (repaglinide, rosiglitazone, paclitaxel, bupropion) within at least 2 weeks or 5 half-lives (whichever is longer) before the planned first dose of study drug.\n14. Participating in another CTIMP trial within 5 half-lives of the last administered dose of an investigational medicinal product.\n15. Participants eligible for other antiviral treatment according to DHSC criteria, or those otherwise eligible for CST9a.","ALL","18 Years",{"count":20,"type":21},600,"ESTIMATED","INTERVENTIONAL",[24,25],"PHASE1","PHASE2","The AGILE platform master protocol allows incorporation of a range of identified and yet-to-be-identified candidates as potential treatments for adults with COVID-19 into the trial. Candidates will be added into the trial via candidate-specific trial (CST) protocols of this master protocol as appendices. Having one master protocol ensures different candidates are evaluated in the same consistent manor and opening up new trials for new candidates is more efficient. Inclusion of new candidates will be based on pre-clinical data, evidence in the clinical setting and GMP capabilities.",[28],"Covid19",[30,31,32,33,34],"SARS coronavirus 2","SARS-CoV-2","Phase I","Phase II","Platform trial","RECRUITING","2026-05-27",{"date":38,"type":39},"2026-06-01","ACTUAL",{"date":41,"type":39},"2020-07-03",{"date":43,"type":21},"2027-03-31",{"name":45,"class":46},"University of Liverpool","OTHER",7,{"id":49,"slug":50,"hasResults":11,"nctId":51,"briefTitle":52,"officialTitle":52,"acronym":4,"eligibilityCriteria":53,"healthyVolunteers":54,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":55,"targetDuration":4,"studyType":57,"phases":4,"briefSummary":58,"conditions":59,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":61,"lastUpdatePostDateStruct":62,"startDateStruct":64,"completionDateStruct":66,"leadSponsor":68,"locationsCount":69},"100230861","validation-of-drug-assays-in-various-biological-matrices-100230861","NCT02283112","Validation of Drug Assays in Various Biological Matrices","Inclusion Criteria:\n\n* \\> 18 years of age\n\nExclusion Criteria:\n\n* Unable to give informed consent",true,{"count":56,"type":21},100,"OBSERVATIONAL","This study aims to ensure that assays that measure drug concentrations are accurate and precise in different matrices when quantified using high performance liquid chromatography -tandem mass spectrometry (HPLC-MS\u002FMS). The study involves collecting samples of various bodily fluids to quantify antimicrobials, antivirals, oral contraceptives and erectile dysfunction agents. Samples will also be obtained from individuals not receiving these medications for quality control purposes.",[60],"Infection","2026-05-06",{"date":63,"type":39},"2026-05-11",{"date":65,"type":39},"2014-10",{"date":67,"type":21},"2027-12-31",{"name":45,"class":46},1,{"id":71,"slug":72,"hasResults":11,"nctId":73,"briefTitle":74,"officialTitle":74,"acronym":4,"eligibilityCriteria":75,"healthyVolunteers":54,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":76,"targetDuration":4,"studyType":22,"phases":77,"briefSummary":79,"conditions":80,"keywords":83,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":87,"lastUpdatePostDateStruct":88,"startDateStruct":90,"completionDateStruct":92,"leadSponsor":94,"locationsCount":69},"100621304","fast-food-online-delivery-purchase-behaviour-in-the-presence-and-absence-of-price-based-incentives-100621304","NCT07368881","Fast Food Online Delivery Purchase Behaviour in the Presence and Absence of Price-based Incentives","Inclusion Criteria:\n\n* Able to order and pay for a takeaway pizza for delivery today or tomorrow\n* Currently reside in select postcode areas\n\n  * Manchester (M13 store): M1, M2, M3, M4, M5, M11, M12, M13, M14, M15, M16, M18, M19\n  * Liverpool (L3 store): L1, L2, L3, L4, L5, L6, L8, L13, L15\n  * Birmingham (B27 store): B9, B10, B11, B12, B13, B25, B26, B27, B28, B33, B90, B91, B92\n* Over the age of 18 years\n* Report having used food delivery services in the last year\n\nExclusion Criteria:\n\n* Partaking in a fast or other restrictive eating (e.g. for religious or health reasons) at time of participation\n* A previous eating disorder diagnosis\n* Currently on appetite-suppressing medication\n* Dietary restrictions\u002Fintolerances including:\n\n  * Gluten-free\n  * Dairy-free\n  * Sugar-free",{"count":20,"type":21},[78],"NA","Consumption of out-of-home (OOH) food is associated with significantly greater energy and less-healthy nutrient (i.e. fats, salt and sugar) intake. The price of food is a key consideration of food choice, particularly for individuals of lower socioeconomic position (SEP). Little research to date has examined the causal effect of removing price-based incentives on purchasing behaviour in OOH food settings. One online randomised controlled trial explored the effect of removing three types of price-based incentives individually and in combination, on food choice through a virtual food delivery platform. This study found that energy selection was 7-8% lower when price incentives were removed. While not statistically significant, Bayes factors indicted that data comparing control vs \"all promotions removed\" conditions were inconclusive (BF10 = 0.55) and therefore could not provide support for the alternative or null hypotheses. A limitation of this study is that the outcome was hypothetical food choice. As participants would not pay for or receive their selected meals, the prices of foods may have been less salient, thus reducing the potential for impact. In the present study, exploring real-world consumer behaviour (as opposed to hypothetical choice) will better determine the potential impact of removing price-based incentives in the OOH food sector.",[81,82],"Food Purchases","Eating Behaviour",[84,85,86],"Obesity","Food pricing","Price promotions","2026-04-30",{"date":89,"type":39},"2026-05-01",{"date":91,"type":39},"2026-02-24",{"date":93,"type":21},"2026-06-30",{"name":45,"class":46},{"id":96,"slug":97,"hasResults":11,"nctId":98,"briefTitle":99,"officialTitle":100,"acronym":101,"eligibilityCriteria":102,"healthyVolunteers":54,"sex":17,"minAge":18,"maxAge":103,"enrollmentInfo":104,"targetDuration":4,"studyType":57,"phases":4,"briefSummary":106,"conditions":107,"keywords":111,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":87,"lastUpdatePostDateStruct":118,"startDateStruct":119,"completionDateStruct":121,"leadSponsor":122,"locationsCount":69},"100534200","do-patients-with-acl-tears-demonstrate-weakness-of-the-soleus-muscle-100534200","NCT06235736","Do Patients With ACL Tears Demonstrate Weakness of the Soleus Muscle?","Do Patients With Anterior Cruciate Ligament (ACL) Tears Demonstrate Weakness of the Soleus Muscle?","ACL","Inclusion Criteria:\n\nACL tear participants:\n\n* MRI-confirmed ACL tear.\n* Participant is willing and able to give informed consent in writing for participation in the study.\n* Male or Female, aged 18 years to 55 years of age.\n* No contraindications to strength testing (see exclusion criteria).\n\nNormative values from healthy individuals:\n\n* No current or previous history of significant lower limb injury, or a history of previous minor injury that is symptomatic at the time of recruitment.\n* No previous lower limb surgery.\n* No course of medication, whether prescribed or over the counter, other than vitamins and mineral supplements or, for females, oral contraceptives.\n\nExclusion Criteria:\n\n* History of chronic musculoskeletal disease or disorder in either leg that may put the participants at risk because of participation in the study including non-united fractures, epilepsy, cardiac insufficiency, severe peripheral vascular disease, aneurysms, anticoagulant therapy, recent (\\<3 months) radiotherapy or chemotherapy, long term steroid use (\\>3 months), pregnancy, neurological disorders (e.g., Parkinson's disease), skin conditions at point of force testing, severe osteoporosis, malignancy, rheumatoid arthritis.\n\n  * Conditions or symptoms that may influence the result of the study, or the participant's ability to participate in the study including pain, limited range of motion, knee effusion, or anaemia.","55 Years",{"count":105,"type":21},55,"The goal of this prospective, cross-sectional study is to test the strength of the soleus muscle in participants who have a ACL tear confirmed by MRI. Previous studies have shown that the soleus muscle, which one of the muscles situated in the calf, decreases mechanical loading on the ACL. Therefore, we aim to test soleus muscle strength using a seated plantar flexor test.\n\nThe main questions we aim to answer are:\n\n* Do patients with ACL tears demonstrate inter-limb soleus strength asymmetry (\\>10%)\n* Do patients with ACL tears have soleus muscle weakness compared with uninjured (normative) participants?\n* Do changes in soleus strength values correlate with patient reported outcomes and stability, as measured by the IKDC questionnaire?\n\nTo achieve this the VALD force frame will be used as the testing device for plantar flexor strength testing. This device records the force generated by the movement. This will be repeated three times on each leg as part of the testing procedure. Furthermore, as part of the testing procedure participants will be required to fill out an IKDC form to assess their knee stability. Interrater reliability of the force frame will be investigated.\n\nFurther data from participants without ACL tears will be used to compare results. Thus allowing us to see if people with ACL tears have a weakness in the soleus muscle.",[108,109,110],"ACL Tear","ACL-injury","ACL - Anterior Cruciate Ligament Rupture",[112,101,113,114,115,116,117],"Acute cruciate ligament","soleus muscle","physiotherapy","orthopaedics","trauma","rehabilitation",{"date":61,"type":39},{"date":120,"type":39},"2024-01-17",{"date":67,"type":21},{"name":45,"class":46},{"id":124,"slug":125,"hasResults":11,"nctId":126,"briefTitle":127,"officialTitle":128,"acronym":4,"eligibilityCriteria":129,"healthyVolunteers":54,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":130,"targetDuration":4,"studyType":22,"phases":131,"briefSummary":132,"conditions":133,"keywords":136,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":143,"lastUpdatePostDateStruct":144,"startDateStruct":145,"completionDateStruct":147,"leadSponsor":149,"locationsCount":69},"100619081","supermarket-labelling-and-taxation-study-100619081","NCT07339982","Supermarket Labelling and Taxation Study","The Effect of Nutrient Warning vs. Traffic Light Labels and Taxation on Food Purchasing Behaviour Among UK Consumers: a Randomised Controlled Trial","Inclusion Criteria:\n\n* Are a UK resident\n* Are aged 18 years and above\n* Are fluent in English\n* Have access to a laptop\u002Fdesktop computer with internet access\n* Are willing to order, pay for, and eat a ready meal from Tesco for an evening meal\n* Can access Home Delivery\u002FWhoosh\u002FClick \\& Collect from Tesco\n* Do not have any major dietary restrictions (e.g., vegetarian, vegan, gluten-free)\n* Are not on any medication which affects appetite\n* Do not have a current or past eating disorder diagnosis",{"count":20,"type":21},[78],"Participants will be assigned to one of four conditions: (i) nutrient warning labelling and no taxation, (ii) nutrient warning labelling and taxation, (iii) current traffic light labelling and taxation or (iv) a control condition (current traffic light labelling and no taxation). Participants will complete a food ordering task using a simulated online supermarket resembling a major UK retailer (Tesco), before purchasing their selected items for delivery\u002Fcollection via the retailer. Food choices will be recorded, and participants will self-report intake of purchased food items.",[134,135],"Nutrition Labeling","Tax Policy",[137,138,139,140,141,142],"front-of-pack labelling","nutrition labelling","traffic light label","nutrient warning label","taxation","food choice","2026-04-29",{"date":61,"type":39},{"date":146,"type":39},"2026-02-02",{"date":148,"type":21},"2026-08-01",{"name":45,"class":46},{"id":151,"slug":152,"hasResults":11,"nctId":153,"briefTitle":154,"officialTitle":155,"acronym":156,"eligibilityCriteria":157,"healthyVolunteers":54,"sex":17,"minAge":158,"maxAge":4,"enrollmentInfo":159,"targetDuration":4,"studyType":57,"phases":4,"briefSummary":160,"conditions":161,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":164,"lastUpdatePostDateStruct":165,"startDateStruct":167,"completionDateStruct":169,"leadSponsor":171,"locationsCount":69},"100576350","the-role-of-ectopic-fat-and-heart-attack-risk-in-hiv-100576350","NCT06784154","The Role of Ectopic Fat and Heart Attack Risk in HIV","The Association of Ectopic Fat and Cardiovascular Disease in People Living With HIV and General Populations: A Cross Sectional Analysis","BHIVA","Inclusion Criteria:\n\n* • \\>40 years\n\n  * HIV-positive\n  * Stable ART for \\>6 months with two VL \\\u003C40 copies\u002Fml based on local testing protocols\n  * CD4 count \\>200cells\u002Fmm3 for \\>2 years from recruitment Inclusion Criteria (all)\n  * Understand the study procedures, able to comply with study procedures and voluntarily agree to participate by giving informed written consent\n\nExclusion Criteria:\n\n* Subjects unable to comply with the study protocol\n* History of severe renal impairment (eGFR \\\u003C30ml\u002Fmin)\n* History of severe hepatic impairment (Child Pugh Score \\>9)\n* Active hepatitis B or hepatitis C\n* Any active illness, which in the opinion of the investigator precludes participation in the study.\n* History of cancer\n* Active illicit intravenous drug use\n* Investigators may decide the subject cannot proceed if there are any relevant other abnormal results in screening assessments\n* History or current GLP-1 agonist use\n* For female subjects: pregnancy or breast feeding at screening.\n* Subjects currently taking: Atypical antipsychotics, omega 3 supplements, Telmisartan\u002FIrbesartan, Thiazolidinediones or regular NSAID use.\n* Familial hypercholesterolaemia","40 Years",{"count":56,"type":21},"This study is designed to investigate differences between people living with HIV (PLWHIV) and general populations on how the body utilises and stores energy. This study uses magnetic resonance imaging (MRI) to measure fat around the body organs including the heart and liver. The fat around body organs, also known as visceral fat, is known to be associated with metabolic syndrome and a risk factor for developing heart attacks and strokes.\n\nMRI scans are used frequently in hospitals to diagnose a range of conditions. These scans use radio waves to measure protons in body tissues. The machines can reconstruct tissues using complex algorithms to form composite images of body structures. MRI scans do not use ionising radiation and there is no risk to undertaking an MRI in terms of radiation.\n\nWe often use MRI scans to assess the hearts' structure and function. In addition, we can use specific MRI sequences to assess the integrity of heart muscle. Heart MRI is often considered the gold standard imaging technique to assess the heart and heart muscle disease. This sub-study will use multiple MRI sequences to assess the heart and the liver. We are aiming to investigate any changes in heart and liver fat. In addition, we will assess any changes in fat levels within the heart muscle cells whilst also assessing for any change in the way the heart is functioning.\n\nPLWHIV have roughly double the risk of heart attacks compared to general populations. Previous studies have demonstrated that this increased risk may arise from the way in which fat is stored and metabolised in the body. We hope this study will give insight into why HIV-positive individuals have increased risks of heart attacks and how reducing visceral fat may reduce risk. It may lead to further medicines or treatment strategies to reduce the risk of heart attacks in HIV-positive individuals.",[162,163],"Cardiometabolic Syndrome","Hiv","2026-02-17",{"date":166,"type":39},"2026-02-19",{"date":168,"type":39},"2024-08-01",{"date":170,"type":21},"2027-06-30",{"name":45,"class":46},{"id":173,"slug":174,"hasResults":11,"nctId":175,"briefTitle":176,"officialTitle":176,"acronym":177,"eligibilityCriteria":178,"healthyVolunteers":11,"sex":179,"minAge":18,"maxAge":4,"enrollmentInfo":180,"targetDuration":4,"studyType":22,"phases":182,"briefSummary":184,"conditions":185,"keywords":187,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":164,"lastUpdatePostDateStruct":189,"startDateStruct":190,"completionDateStruct":192,"leadSponsor":194,"locationsCount":69},"100487711","phase-4-doravirine-dose-optimisation-in-pregnancy-100487711","NCT05630638","Doravirine Dose Optimisation in Pregnancy","DoraDO","Inclusion Criteria:\n\n* Women ≥ 18 years old\n* Ability to give informed consent prior to participation\n* Willing and able to comply with all study requirements\n* HIV positive\n* Pregnant (initiating cART ≥ 12 weeks and \\\u003C 26 weeks gestation)\n* Intention to breastfeed postpartum\n\nExclusion Criteria:\n\n* Received any cART in preceding 6 months\n* Chronic hepatitis B (HBV) infection with clinical evidence of transaminitis\n* Elevations in serum levels of alanine aminotransferase (ALT) \\> 5 times the upper limit of normal (ULN) or ALT \\> 3xULN and bilirubin \\>2xULN (with \\> 35 % direct bilirubin)\n* Previous documented failure of an NNRTI-containing cART regimen\n* Previous history of hypersensitivity to any ARV\n* Concomitant medication which are inducers of SoC and DOR metabolism (e.g. rifampicin, anti-epileptic agents, rifabutin, St John's Wort, mitotane, enzalutamide, lumacaftor). Contraindicated medications can be found on Liverpool Drug Interactions website (hiv-druginteractions.org)\n* Participants with rare hereditary problems of galactose intolerance, total lactase deficiency or glucose-galactose malabsorption cannot take DOR as the tablet contains lactose monohydrate\n* Clinical depression or clinical judgment suggests increased risk of suicidality","FEMALE",{"count":181,"type":21},76,[183],"PHASE4","A randomised, open label, controlled PK standard of care vs doravirine plus 2 nucleoside reverse transcriptase inhibitors backbone in pregnant women initiating combination antiretroviral therapy in the second trimester of pregnancy.",[186],"HIV",[188],"Pregnancy",{"date":166,"type":39},{"date":191,"type":39},"2023-10-10",{"date":193,"type":21},"2028-07",{"name":45,"class":46},{"id":196,"slug":197,"hasResults":11,"nctId":198,"briefTitle":199,"officialTitle":200,"acronym":201,"eligibilityCriteria":202,"healthyVolunteers":11,"sex":17,"minAge":203,"maxAge":204,"enrollmentInfo":205,"targetDuration":4,"studyType":22,"phases":207,"briefSummary":208,"conditions":209,"keywords":214,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":164,"lastUpdatePostDateStruct":220,"startDateStruct":222,"completionDateStruct":224,"leadSponsor":226,"locationsCount":227},"100462841","an-exploratory-study-of-arginine-supplementation-and-the-postoperative-immune-response-100462841","NCT05306925","An Exploratory Study of Arginine Supplementation and the Postoperative Immune REsponse","An Exploratory Study of Arginine Supplementation and the Postoperative Immune REsponse (ASPIRE)","ASPIRE","Inclusion Criteria:\n\n* Preterm infants born \\\u003C30 weeks gestation requiring laparotomy\u002Fmajor bowel surgery or diagnosed with necrotising enterocolitis (Modified Bell's Stage II or higher) before discharge\n* Term and near term infants (born\\>35 weeks gestation) requiring laparotomy\u002Fmajor bowel surgery in the first 3 days of life (gastroschisis; major bowel atresias expected to require at least 7 days of PN)\n\nExclusion Criteria:\n\n* Infants who are unlikely to survive because of poor immediate postoperative condition\n* Infants known (or suspected to have) a diagnosis of inborn error of metabolism or serious liver dysfunction\n* Parents who are unable to give informed consent","22 Weeks","44 Weeks",{"count":206,"type":21},48,[78],"ASPIRE is a nutrition study focusing on the effect of arginine supplementation on immune function in postoperative infants.\n\nThe investigators will explore the effect of current intravenous feeding (parenteral nutrition (PN)) formulations and oral arginine supplementation on blood arginine levels and the genes that are involved in body nutrition and fighting infection in babies who have had major bowel surgery or been diagnosed with necrotising enterocolitis. The investigators will undertake an exploratory physiological study across two sites under which are part of a single neonatal partnership. 48 infants will be recruited; 24 preterm infants and 24 term\u002Fnear term infants. 16 of these infants (8 preterm and 8 term\u002Fnear term) will be supplemented with arginine in both oral and parenteral form, 16 infants will receive arginine supplementation in oral form alone and 16 infants will receive standard nutrition with no arginine supplement. The investigators will record nutritional intake and routine biochemical testing data (which includes amino acid levels) collected over the first 30 days post surgery or post NEC diagnosis. The investigators will take blood for analysis at prespecified intervals for RNA sequencing, ammonia and metabolomics. RNA sequencing findings will allow the investigators to describe the effect of arginine on gene activity in postoperative infants\n\nThe investigators hypothesise that arginine supplementation will result in changes in gene expression that are consistent with changes in T-cell function and associated inflammatory pathways.",[210,211,212,213],"Preterm","Surgery","Nutritional Deficiency","Immune System and Related Disorders",[215,216,217,218,219],"Neonate","Arginine","Postoperative","Immune function","Nutrition",{"date":221,"type":39},"2026-02-18",{"date":223,"type":39},"2022-04-14",{"date":225,"type":21},"2026-12-31",{"name":45,"class":46},2,{"id":229,"slug":230,"hasResults":11,"nctId":231,"briefTitle":232,"officialTitle":233,"acronym":4,"eligibilityCriteria":234,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":235,"targetDuration":4,"studyType":22,"phases":237,"briefSummary":238,"conditions":239,"keywords":241,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":245,"lastUpdatePostDateStruct":246,"startDateStruct":248,"completionDateStruct":250,"leadSponsor":251,"locationsCount":69},"100619080","food-choice-among-individuals-with-an-eating-disorder-diagnosis-100619080","NCT07339969","Food Choice Among Individuals With an Eating Disorder Diagnosis","The Impact of Warning Labels vs Traffic Light Labels on Food Choice and Negative Emotional Response in an Eating Disorder Population Group","Inclusion Criteria:\n\n* Current or past eating disorder diagnosis\n* Aged 18+\n* Live in the UK\n* Fluent English speaker\n\nExclusion Criteria:\n\n* Currently partaking in a fast or any other restrictive eating\n* Any dietary restrictions\u002Fintolerances (eg. Vegan, Gluten-free, etc.)",{"count":236,"type":21},246,[78],"The aim of this study is to understand the impact of front of pack labelling systems such as, warning labels and traffic light labels on food choice and negative emotional response in an eating disorder(s) population group. Participants will be recruited to take part in an online study where they will be required to make hypothetical food choices. Participants will complete a baseline no label task, before being randomly assigned to (1) warning label group, (2) traffic light label group, or (3) no label group in which they will complete the same task a second time (mixed design). Each participant, irrespective of the group will be asked to complete five trials within the main task. Participants will view a selection of six packaged food items for scenarios involving labels predominately relating to (1) sugar, (2) salt, (3) fat, (4) saturated fat, and (5) calorie content of the food products. Three items will be 'high in' that particular nutrient and three items will not be high in that nutrient. Participants will be shown all six options at once and will be asked to choose one item. In total, participants will choose five different items, one from each trial. After participants have made their food choices for the second task, they will be asked questions about the task they have just completed.",[240],"Eating Behavior Disorders",[138,242,142,243,244],"eating disorders","warning labels","traffic light labels","2026-01-05",{"date":247,"type":39},"2026-01-14",{"date":249,"type":39},"2025-11-13",{"date":89,"type":21},{"name":45,"class":46},{"id":253,"slug":254,"hasResults":11,"nctId":255,"briefTitle":256,"officialTitle":257,"acronym":258,"eligibilityCriteria":259,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":260,"targetDuration":4,"studyType":22,"phases":262,"briefSummary":263,"conditions":264,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":266,"lastUpdatePostDateStruct":267,"startDateStruct":269,"completionDateStruct":271,"leadSponsor":273,"locationsCount":227},"100486568","assessment-of-a-robotic-exoskeleton-for-upper-limb-rehabilitation-100486568","NCT05615766","Assessment of a Robotic Exoskeleton for Upper Limb Rehabilitation","EXO4UL- Assessment of a Robotic Exoskeleton for Upper Limb Rehabilitation of Spinal Cord Injured Patients","Exo4UL","Inclusion Criteria:\n\n* Age 18+ years.\n* The levels of C5 C6 Asia C\u002FD would provide individuals with elbow and hand impairment and potentially functional shoulder movements. C7, C8 individuals could also benefit from the hand component of the device.\n* Some gross shoulder movement at start of the trial to enable changes at the elbow\u002Fhand, to have the greatest potential for functional change.\n* Preservation of hand sensation as base for motor restoration.\n* Some sitting balance would give the best opportunity for the arm to be released for functional upper limb activity.\n* EMG (muscle activity) evidence of active finger flexion, extension and elbow flexion extension Grade 1-2.\n* Minimal or No community functional use of upper limb at start of trial.\n* Spasticity MAS 1-3\u002F5.",{"count":261,"type":21},9,[78],"Rehabilitation robotics has the potential to facilitate rehabilitation at home and empower people with spinal injuries to self-manage increasing their independence and improving their quality of life.\n\nThe objective of this study is to assess for the first time in the NHS the efficacy of a commercial robotic orthosis for upper limb rehabilitation in patients with spinal cord injury. The device is produced by Myomo (myomo.com) which is an American company. We will be assessing the wearable robotic orthosis also known as robotic exoskeleton in two different neuro-rehabilitation centres: National Spinal injuries Unit in Glasgow (Scotland) and The Robert Jones and Agnus Hunt Orthopaedic Hospital in Oswestry (England). The study will involve nine spinal cord injured tetraplegic inpatients in total.\n\nPatients will follow a twelve-week rehabilitation programme with three to four sessions per week in addition to their usual care and rehabilitation. Each session lasts for approximately 45 minutes. Participants arm function, range of motion, spasticity level will be measured before, half-way and at the end of the programme to assess change in these and other parameters. Training will focus on the dominant arm of the patient and compared to the other arm at every assessment stage.\n\nWe shall evaluate therapists' and patients' satisfaction with the commercial device in addition to assessing various clinical measures to evaluate the efficacy of using the robotic orthosis in rehabilitation and recovery of arm function.",[265],"Spinal Cord Injuries","2025-08-27",{"date":268,"type":39},"2025-09-04",{"date":270,"type":39},"2022-09-01",{"date":272,"type":21},"2026-03",{"name":45,"class":46},{"id":275,"slug":276,"hasResults":11,"nctId":277,"briefTitle":278,"officialTitle":279,"acronym":280,"eligibilityCriteria":281,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":282,"enrollmentInfo":283,"targetDuration":4,"studyType":22,"phases":285,"briefSummary":286,"conditions":287,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":266,"lastUpdatePostDateStruct":289,"startDateStruct":290,"completionDateStruct":292,"leadSponsor":293,"locationsCount":294},"100338271","phase-2-randomised-treatment-of-acute-pancreatitis-with-infliximab-double-blind-placebo-controlled-multi-centre-trial-rapid-i-100338271","NCT03684278","Randomised Treatment of Acute Pancreatitis With Infliximab: Double-blind, Placebo-controlled, Multi-centre Trial (RAPID-I)","Phase IIb, Randomised, Double-blind, Placebo-controlled, Multi-centre Trial of Infliximab With Transcriptomic Biomarker and Mechanism Evaluation in Patients With Acute Pancreatitis.","RAPID-I","Inclusion Criteria:\n\n* Adult patients attending Accident and Emergency (A\\&E) at or admitted to recruiting hospitals via a GP with a new diagnosis of AP established by two of the following three criteria: (1) typical continuous upper abdominal pain; (2) amylase and\u002For lipase three or more times the upper limit of normal; (3) characteristic findings on abdominal imaging (if undertaken urgently by CT or MRI)\n* Patients in whom trial treatment can be started within 36 hours of admission to hospital with a new diagnosis of acute pancreatitis allowing 120 min for preparation of trial medication\n* Patients from whom appropriate consent is obtained (from the patient or their legal representative).\n\nExclusion Criteria:\n\n* Age \\\u003C18 or \\>85\n* Patients with a bodyweight over 200 kg\n* Known previous AP within the last 30 days or chronic pancreatitis\n* Multiple sclerosis, systemic vasculitis, Guillain-Barré syndrome or other demyelinating disorder\n* Known epilepsy\n* Moderate to severe heart failure and\u002For coronary disease (NYHA III\u002FIV)\n* Severe respiratory conditions including cystic fibrosis, severe asthma and severe chronic obstructive pulmonary disease (COPD)\n* On home oxygen or home mechanical ventilation\n* Jaundice and\u002For known advanced liver disease\n* Known cancer for which chemotherapy and\u002For radiotherapy ongoing\u002Fcompleted in last 6 months\n* Known haematological malignancy\n* Known cancer with palliative care\n* Known established infection prior to or suspected infection, including COVID-19, at the time of AP onset\n* Known history of tuberculosis, or household contact with those with tuberculosis or opportunistic infection\n* Known history of infective hepatitis\n* Rare diseases or inborn errors of metabolism that significantly increase the risk of infections, including severe combined immunodeficiency (SCID) and homozygous sickle cell disease\n* Known live vaccine or infectious agent within one month of admission\n* Known immunosuppressive or biologic therapy within one month of admission\n* Known hypersensitivity to infliximab or to inactive components of REMICADE® or to any murine proteins\n* Known pregnancy or lactation at admission\n* Females of childbearing potential who do not agree to use adequate contraception up to 6 months after infliximab infusion\n* Known participation in investigational medicinal product study within last three months.","85 Years",{"count":284,"type":21},290,[25],"This study evaluates the effectiveness and safety of infliximab in the treatment of acute pancreatitis in adults. A third of participants will receive one single dose of infliximab via infusion, another third will receive a higher dose of infliximab via infusion and the final third of participants will receive a placebo infusion.",[288],"Acute Pancreatitis",{"date":268,"type":39},{"date":291,"type":39},"2019-05-01",{"date":43,"type":21},{"name":45,"class":46},13,{"id":296,"slug":297,"hasResults":11,"nctId":298,"briefTitle":299,"officialTitle":300,"acronym":301,"eligibilityCriteria":302,"healthyVolunteers":54,"sex":17,"minAge":303,"maxAge":304,"enrollmentInfo":305,"targetDuration":4,"studyType":57,"phases":4,"briefSummary":307,"conditions":308,"keywords":310,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":314,"lastUpdatePostDateStruct":315,"startDateStruct":317,"completionDateStruct":319,"leadSponsor":321,"locationsCount":69},"100489208","a-platform-study-for-solid-organ-cancers-100489208","NCT05650125","A Platform Study for solId orgaN CancERs","PINCER (A Platform Study for solId orgaN CancERs); an Agile Regional Platform Study to Deliver High Quality Translational Research","PINCER","Inclusion Criteria:\n\n* Biopsy or surgical resection as standard of care\n\nExclusion Criteria:\n\n* Refusal or inability to consent, paediatric patients","16 Years","100 Years",{"count":306,"type":21},2000,"Generating bespoke biosampling protocols for individual tumour specific translational projects is onerous, cumbersome and inefficient. This study aims to provide a broad platform to maximise the unique access to biopsy and resected tumour specimens available from cancer patients to provide a high-quality and efficient source of biosamples for specific translational projects. Access to historical FFPE samples and clinical data, as well as prospective fresh tissue samples, will allow interrogation of the underlying biology of these cancers. Matched pseudoanonymised clinical and radiological data will allow the development of rich high-yield datasets.",[309,211],"Cancer",[211,309,311,312,313],"Translational","Biosample","Cohort","2025-07-29",{"date":316,"type":39},"2025-08-01",{"date":318,"type":39},"2022-01-01",{"date":320,"type":21},"2030-01-01",{"name":45,"class":46},""]